Please login to the form below

Not currently logged in
Email:
Password:

NICE recommends Sutent

The National Institute for Health and Clinical Excellence has recommended Pfizer's Sutent as a possible first line drug treatment for people with advanced and/or metastatic renal cell carcinoma

The National Institute for Health and Clinical Excellence (NICE) has recommended Pfizer's Sutent (sunitinib) as a possible first line drug treatment for people with advanced and/or metastatic renal cell carcinoma. The new guidance applies to mobile patients who are suitable candidates for immunotherapy.  

Sutent was originally reviewed along with Roche's Avastin (bevacizumab), Bayer's Nexavar (sorafenib), and Wyeth's Torisel (temsirolimus) as part of a multiple technology appraisal. In August 2008, NICE advised against the use of all four drugs for this condition, but has since reassessed how it values medicines intended to extend life in terminal patients. In addition, Pfizer has also offered the initial six-week cycle of treatment with Sutent free of charge to the NHS. Guidance on the other three drugs is scheduled to be published in June.

Patient groups have welcomed the decision. Professor Robert Hawkins of Cancer Research UK said in a statement: "I am delighted that Sutent will be available. It will remove a great deal of anxiety and uncertainty for people diagnosed with renal cancer to know that modern, effective treatment is now available to them."

25th March 2009

From: Healthcare

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Sciterion

Sciterion is an award winning specialist healthcare communications consultancy within the Havas Health network of companies. We exist to make...

Latest intelligence

How can pharma engage with key stakeholders on NHS service transformation?
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare consulting team, explain how pharma should make its case for change...
michael elliot
The race for an HIV ‘cure’
Supercharging therapies as pharma and patients work together...
Medopad: the up and coming unicorn transforming remote patient monitoring
Blue Latitude Health speaks to Medopad’s Martha Carruthers to learn how the start-up’s modular apps are helping patients with complex diseases....

Infographics